Article
Biochemistry & Molecular Biology
Maria Kallergi, Alexandros Georgakopoulos, Vassiliki Lyra, Sofia Chatziioannou
Summary: This study investigated the value of tumor measurements in predicting treatment outcomes for Hodgkin's and Non-Hodgkin's lymphomas. Results showed that while SUVmax was the strongest prognostic indicator, automated metabolic tumor volume measurements and expert's metabolic maximum diameter measurements also provided valuable insights. Anatomic tumor measurements had poor prognostic value. The study suggests a paradigm shift towards identifying robust prognostic markers in PET/CT with the use of radiomics.
Article
Biophysics
Carlo Lazzaro, Luca Castagna, Francesco Lanza, Daniele Laszlo, Giuseppe Milone, Luca Pierelli, Riccardo Saccardi
Summary: The study compared the cost-effectiveness of using G-CSF alone versus high-dose cyclophosphamide + G-CSF mobilization in Italian multiple myeloma patients eligible for autograft. The findings revealed that G-CSF alone was a more cost-effective option, demonstrating incremental savings and a higher probability of successful apheresis.
BONE MARROW TRANSPLANTATION
(2021)
Review
Oncology
Chenbo Yang, Yinghao Liang, Jiao Shu, Shuaiyuan Wang, Yichen Hong, Kuisheng Chen, Miaomiao Sun
Summary: Multiple myeloma (MM) is a major hematological malignancy in middle-aged and older individuals, and it seriously harms human health due to drug resistance and high recurrence. Long non-coding RNAs (lncRNAs) play a role in regulating carcinogenesis and cancer progression. MM-associated lncRNAs impact tumor cell features such as proliferation, apoptosis, adhesion, and treatment resistance. This review aims to summarize the roles of lncRNAs in MM, deepen the understanding of this field, and provide insights for developing diagnostic tools and treatment strategies, including biomarkers and targeted lncRNA therapeutics.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Article
Immunology
Kissy Guevara-Hoyer, Jesus Fuentes-Antras, Eduardo de la Fuente-munoz, Miguel Fernandez-Arquero, Fernando Solano, Pedro Perez-Segura, Esmeralda Neves, Alberto Ocana, Rebeca Perez de Diego, Silvia Sanchez-Ramon
Summary: This study aims to explore the shared genomic basis between common variable immunodeficiency (CVID) and non-Hodgkin's lymphoma (NHL), in order to better understand the immunodeficiency phenotype of CVID in NHL. The study found that NHL samples harbored genetic variants associated with CVID, indicating the existence of shared pathological mechanisms and signaling pathways.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Oren Pasvolsky, Denai R. Milton, Mikael Rauf, Sassine Ghanem, Adeel Masood, Ali H. Mohamedi, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Katy Rezvani, Richard Champlin, Elizabeth J. Shpall, Pei Lin, Muzaffar H. Qazilbash
Summary: A retrospective analysis showed that the presence and degree of clonal plasma cells (CPC) in the autograft were highly predictive of inferior progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (autoHCT).
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
M. A. Bekadja, B. Mansour, H. Ouldjeriouat, B. Entasoltan, S. Bouchama, L. Charef, K. Amani, N. Hakiki, F. Bouamama, S. Osmani, M. Brahimi, A. Arabi, R. Bouhass, N. Yafour
Summary: The study demonstrated that the generic of Plerixafor is practically identical to the originator in terms of efficacy and safety when used for mobilizing PBSCs for ASCT in MM and lymphoma patients. Prospective comparisons with traditional auto-HCT regimens are needed to further evaluate the effectiveness of generic Plerixafor.
TRANSFUSION AND APHERESIS SCIENCE
(2021)
Article
Medicine, General & Internal
Jiamei Wu, Yin Zhou, Qingshu Li, Jing Zhang, Yun Mao
Summary: PBNHL is a rare disease with difficult preoperative diagnosis, so it should be considered when encountering cases with Epstein-Barr virus infection and typical imaging findings.
Article
Oncology
Sung-Soo Park, Seung-Hwan Shin, Jung-Yeon Lee, Young-Woo Jeon, Seung-Ah Yhang, Chang-Ki Min
Summary: This study compared the mobilization effects and safety of single-dose etoposide plus G-CSF versus G-CSF alone with risk-adapted plerixafor in MM patients. The findings showed that the etoposide group had a higher count of CD34+ cells collected, but there was no significant difference in the optimal collection rate between the two groups. The etoposide group had higher rates of thrombocytopenia and nausea, but overall adverse events were low in both groups.
Article
Genetics & Heredity
Min-Yue Zhang, George Calin, Ming-Dan Deng, Rex K. H. Au-Yeung, Lu-Qian Wang, Chor-Sang Chim
Summary: This study investigated the function and mechanism of long non-coding RNA NKILA in non-Hodgkin's lymphoma. They found that NKILA was methylated in tumor cell lines, leading to the loss of its tumor suppressor effect and sustained activation of NF-kappa B signaling. The results suggest that NKILA is an important tumor suppressor in DLBCL.
Article
Multidisciplinary Sciences
De Matteis Sara, Cosetta Minelli, Giorgio Broccia, Paolo Vineis, Pierluigi Cocco
Summary: This ecological study investigates the link between COVID-19 incidence, socio-economic covariates, and NHL incidence. The results show that COVID-19 cumulative incidence is positively associated with past NHL incidence, socioeconomic deprivation, and proportion of elderly residents, while negatively associated with urban residency. Further investigation is needed to explore shared susceptibility factors among the plausible underlying mechanisms.
Article
Multidisciplinary Sciences
Giorgio Broccia, Jonathan Carter, Cansu Ozsin-Ozler, Federico Meloni, Sara De Matteis, Pierluigi Cocco
Summary: The incidence of non-Hodgkin's lymphoma (NHL) in Sardinia showed an upward trend from 1974 to 2003, prompting further research on the genetic and environmental factors in the high-risk areas.
Article
Cell Biology
Danfeng Zhang, Jingcao Huang, Fangfang Wang, Hong Ding, Yushan Cui, Yan Yang, Juan Xu, Hongmei Luo, Yuhan Gao, Ling Pan, Yu Wu, Yuping Gong, Liping Xie, Zhigang Liu, Ying Qu, Li Zhang, Weiping Liu, Wenyan Zhang, Sha Zhao, Qing Yi, Ting Niu, Yuhuan Zheng
Summary: Multiple myeloma is a malignancy characterized by plasma cell accumulation in the bone marrow. Within the tumor microenvironment, macrophages in multiple myeloma exhibit pro-myeloma functions, which are modulated by the polycomb-group protein BMI1. Knockout of BMI1 in MM-associated macrophages leads to reduced proliferation, decreased expression of angiogenic factors, and loss of protection against chemotherapy-induced cell death, ultimately negating the pro-myeloma effects of these cells.
CELL DEATH & DISEASE
(2021)
Article
Hematology
Andrew Johnsrud, Abdullah Ladha, Lori Muffly, Parveen Shiraz, Gary Goldstein, Victoria Osgood, Judith A. Shizuru, Laura Johnston, Sally Arai, Wen-Kai Weng, Robert Lowsky, Andrew R. Rezvani, Everett H. Meyer, Matthew J. Frank, Robert S. Negrin, David B. Miklos, Surbhi Sidana
Summary: Comparing stem cell mobilization strategies in multiple myeloma patients, it was found that the success rates and mobilization failure rates were similar between chemomobilization and G-CSF with on-demand PXF, with higher complication rates and lower costs in the latter group.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Review
Pharmacology & Pharmacy
Manon Lernoux, Michael Schnekenburger, Mario Dicato, Marc Diederich
Summary: Multiple myeloma is a biologically complex hematological disorder that is currently incurable. Survival of MM molecular subgroups depends on the expression profiles of specific subsets of anti-apoptotic BCL-2 family members. The use of BCL-2 family protein inhibitors as potential treatments represents a strong rationale for further clinical investigation in MM therapy.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Weifeng Wang, Zhuo Zhang, Xiaocong Deng, Anqi Gu, Xianzhao Chen, Yizheng Cai, Yuting Zhao
Summary: In this case report, a 57-year-old male patient with diffuse large B-cell lymphoma was successfully treated with radiation therapy and medication, achieving complete remission.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Aleksandar Radujkovic, Stefan Fruehauf, W. Jens Zeller, Anthony D. Ho, Julian Topaly
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2010)
Article
Oncology
Aleksandar Radujkovic, Thomas Luft, Peter Dreger, Anthony D. Ho, W. Jens Zeller, Stefan Fruehauf, Julian Topaly
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2014)
Article
Cell & Tissue Engineering
Stefan Fruehauf, Marlon Romano Vedwijk, Timon Seeger, Mario Schubert, Stephanie Laufs, Julian Topaly, Patrick Wuchter, Falk Dillmann, Volker Eckstein, Frederik Wenz, Hartmut Goldschmidt, Anthony Dick Ho, Gary Calandra
Article
Cell & Tissue Engineering
Marlon R. Veldwijk, Leopold Sellner, Marius Stiefelhagen, Juergen A. Kleinschmidt, Stephanie Laufs, Julian Topaly, Stefan Fruehauf, W. Jens Zeller, Frederik Wenz
Letter
Hematology
Aleksandar Radujkovic, Peter Dreger, Ute Hegenbart, Eike C. Buss, Thomas Luft, Anthony D. Ho, Stefan Fruehauf, Julian Topaly
EUROPEAN JOURNAL OF HAEMATOLOGY
(2014)
Article
Oncology
Leopold Sellner, Marlon R. Veldwijk, Juergen A. Kleinschmidt, Stephanie Laufs, Julian Topaly, Stefan Fruehauf, W. Jens Zeller, Frederik Wenz
LEUKEMIA & LYMPHOMA
(2011)
Article
Biophysics
S. Fruehauf, J. Klaus, J. Huesing, M. R. Veldwijk, E. C. Buss, J. Topaly, T. Seeger, L. W. J. Zeller, T. Moehler, A. D. Ho, H. Goldschmidt
BONE MARROW TRANSPLANTATION
(2007)
Article
Oncology
Stefan Fruehauf, Julian Topaly, Eike C. Buss, Thomas Fischer, Oliver G. Offmann, Bertold Emmerich, Martin C. Muller, Peter Schuld, Leopold Balleisen, Rbdiger Hehlmann, Anthony D. Ho, Andreas Hochhaus
Article
Oncology
Aleksandar Radujkovic, Julian Topaly, Stefan Fruehauf, W. Jens Zeller
ANTICANCER RESEARCH
(2006)
Review
Cell & Tissue Engineering
S Fruehauf, T Seeger, J Topaly
Article
Oncology
A Radujkovic, M Schad, J Topaly, MR Veldwijk, S Laufs, BS Schultheis, A Jauch, JV Melo, S Fruehauf, WJ Zeller
Letter
Hematology
J Topaly, M Schad, S Laufs, JV Melo, WJ Zeller, S Fruehauf
BRITISH JOURNAL OF HAEMATOLOGY
(2003)
Article
Cell Biology
S Fruehauf, J Topaly, M Schad, P Paschka, H Gschaidmeier, WJ Zeller, A Hochhaus, AD Ho
JOURNAL OF LEUKOCYTE BIOLOGY
(2003)
Article
Cell & Tissue Engineering
KZ Nagy, S Laufs, B Gentner, S Naundorf, K Kuehlcke, J Topaly, EC Buss, WJ Zeller, S Fruehauf